Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Rubius Therapeutics Inc (NQ: RUBY )

26.62 +1.48 (+5.89%)
Streaming Delayed Price Updated: 3:45 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Rubius Therapeutics Inc

< Previous 1 2 3 Next >
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
From GlobeNewswire News Releases
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
From GlobeNewswire News Releases
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating... 
From Business Wire News Releases
Thinking about buying stock in Arbutus Biopharma, Aemetis, FuboTV, Rubius Therapeutics, or Lithium Americas Corp?
InvestorsObserver issues critical PriceWatch Alerts for ABUS, AMTX, FUBO, RUBY, and LAC. 
From PR Newswire
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental... 
From PR Newswire
Rubius Therapeutics Prices Upsized Public Offering of Common Stock
From GlobeNewswire News Releases
Rubius Therapeutics Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
From GlobeNewswire News Releases
Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
From GlobeNewswire News Releases
Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meet
From GlobeNewswire News Releases
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target
Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The... 
From PR Newswire
Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
From GlobeNewswire News Releases
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
From GlobeNewswire News Releases
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
From GlobeNewswire News Releases
Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Financialnewsmedia.com News Commentary 
From PR Newswire
Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
From GlobeNewswire News Releases
Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
From GlobeNewswire News Releases
Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
From GlobeNewswire News Releases
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo 
From GlobeNewswire News Releases
Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
From GlobeNewswire News Releases
Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
RTX-321 Induces Antigen-Specific Stimulation Combined with Broad Stimulation of Innate and Adaptive Immune Responses 
From GlobeNewswire News Releases
Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
From GlobeNewswire News Releases
Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
From GlobeNewswire News Releases
Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
From GlobeNewswire News Releases
Rubius Therapeutics to Participate at Upcoming Investor Conferences
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.